← Back to Clinical Trials
Recruiting NCT07277816

NCT07277816 Photo-experiencing and Reflective Listening (PEARL) to Promote Healing Engagement for Survivors of Violence

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07277816
Status Recruiting
Phase
Sponsor Temple University
Condition Violence and Victimization
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-12-01
Primary Completion 2026-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
PEARL (Photo-experiencing and Reflective Listening)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-12-01 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if a photo-elicitation intervention called PEARL (Photo-experiencing and Reflective Listening) can promote healing engagement in survivors of interpersonal violence. It will also learn about the feasibility and acceptability of PEARL. The main questions it aims to answer are: Does PEARL reduce barriers to help-seeking for trauma? Does PEARL improve trauma coping self-efficacy? Does PEARL change post-trauma cognitions and readiness for recovery? Is PEARL feasible and acceptable to survivors of interpersonal violence? Researchers will compare people who receive PEARL immediately to people on a waitlist (who receive PEARL three months later) to see if PEARL improves healing engagement and help-seeking behaviors. Participants will: * Complete baseline surveys about their trauma history, mental health, healing, and help-seeking behaviors * Be randomly assigned to receive PEARL immediately or after a 3-month wait * Receive a photography-focusing prompt and create photos over two weeks (those in the immediate group or after the waiting period) * Participate in a reflective listening interview about their photos * Complete follow-up surveys immediately after the intervention and one month later * Participate in a one-month follow-up interview about their experience

Eligibility Criteria

Inclusion Criteria: * Age 18 years or older * History of interpersonal violence (IV) - identifies as a survivor of interpersonal violence * Able to complete an interview in English * Able to provide informed consent Exclusion Criteria: * Under 18 years of age * Does not identify as a woman (male participants excluded) * No history of interpersonal violence * Unable to complete an interview in English * Unable to provide informed consent

Contact & Investigator

Central Contact

Laura M Sinko, PhD, MSHP, RN

✉ laura.sinko@temple.edu

📞 9732140617

Principal Investigator

Laura Sinko, PhD, MSHP, RN

PRINCIPAL INVESTIGATOR

Temple University

Frequently Asked Questions

Who can join the NCT07277816 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Violence and Victimization. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07277816 currently recruiting?

Yes, NCT07277816 is actively recruiting participants. Contact the research team at laura.sinko@temple.edu for enrollment information.

Where is the NCT07277816 trial being conducted?

This trial is being conducted at Philadelphia, United States.

Who is sponsoring the NCT07277816 clinical trial?

NCT07277816 is sponsored by Temple University. The principal investigator is Laura Sinko, PhD, MSHP, RN at Temple University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology